Table 1. therapeutic antibodies in Phase 3 clinical studies of non-cancer indications
Sponsoring companyINN or code nameMolecular typeTarget(s)Current
phasePhase 3 indications
AmgenEvolocumab, AMG 145Human igG2PcsK-9Phase 3Hypercholesterolemia;
hyperlipidemia
regeneron; sanofiAlirocumab,Hypercholesterolemia; acute
rEGn-727, sAr236553Human igG1PcsK-9Phase 3coronary syndrome
Amgenromosozumab, Postmenopausal osteopo-
AMG785Humanized igG2sclerostinPhase 3rosis
MerckActoxumab + bezlotox-
umab, MK-3415AHuman igG1c. difficile enterotoxin
A and BPhase 3c. difficile infection
XBiotech, inc.MABp1HumaniL-1 αPhase 3cachexia in cancer patients
Xoma; servierGevokizumabHumanized igG2iL-1 βPhase 3non-infectious uveitis
Asthma; hypereosinophilic
GlaxosmithKlineMepolizumabHumanized igG1iL-5Phase 3syndrome; coPd with eosin-
ophilic bronchitis
tevareslizumabHumanized igG4iL-5Phase 3Eosinophilic asthma
Janssen research &
development LLcsirukumabHuman igG1iL-6Phase 3rheumatoid arthritis
regeneron; sanofisarilumab, sAr153191,
rEGn88Human igG1iL-6r subunit aPhase 3rheumatoid arthritis
Hoffmann-La rocheLebrikizumabHumanized igG4iL-13Phase 3severe asthma
Eli Lilly and co.ixekizumab, LY2439821Humanized igG4iL-17aPhase 3Psoriasis, psoratric arthritis,
plaque psoriasis
rheumatoid or psoriatic
novartis PharmaceuticalssecukinumabHuman igG1iL-17aPhase 3arthritis; ankylosing spondy-
litis; psoriasis
Brodalumab, AMG827, Plaque psoriasis, pustular
Amgen; Kyowa Hakko KirinKHK4827Human igG2iL-17rPhase 3psoriasis and psoriatic eryth-
roderma
Mercktildrakizumab,
MK-3222Humanized igG1iL-23 p19 subunitPhase 3Plaque psoriasis
Eli Lilly and co.tabalumab, LY2127399Human igG4BLysPhase 3sLE
GenentechocrelizumabHumanized igG1cd20Phase 3Multiple sclerosis
UcBEpratuzumabHumanized igG1cd22Phase 3sLE
Hoffmann-LarocheGantenerumabHuman igG1Amyloid bPhase 3Alzheimer disease
Eli Lilly and co.solanezumabHumanized igG1Amyloid bPhase 3Alzheimer disease
note: table compiled from information available as of April 25, 2013. Abbreviations: cd, cluster of differentiation; iL, interleukin; PcsK9, proprotein convertase subtilisin/kexin type; sLE, systemic lupus erythematosus.
200 mg tildrakizumab at week 0 and week 4, and then every Rilotumumab (Amgen) is a human IgG2 targeting human 12 weeks until study end or participant discontinuation. The com-hepatocyte growth factor/scatter factor (HGF/SF) that blocks parator is placebo. In the 54-week NCT01729754 study in the binding of HGF/SF to its receptor MET, thereby inhibiting the same indication, patients receive the same doses of tildrakizumab, MET signaling pathways. The mAb is undergoing evaluation but the study includes 50 mg etanercept as well as placebo as in a Phase 3 study (NCT01697072) of chemotherapy (epirubi-comparators. Both studies are followed by an optional long-term cin, cisplatin and capecitabine) with rilotumumab or placebo safety extension study. The two Phase 3 studies have estimated for untreated advanced MET-positive gastric or gastresopha-primary completion dates of June and July 2015, respectively.geal junction adenocarcinoma. Rilotumumab or placebo is doc.guandang.net mAbs 515©2013 Landes Bioscience. Do not distribute.
2013年中国单克隆抗体药物市场深度调研报告_经济/市场_经管营销_专业资料。单克隆...年中国单克隆抗体药物行业产品市场价格回顾 第二节 中国单克隆抗体药物行业产品...
临床Ⅰ期与临床Ⅱ期研究 与开发的各类生物技术药物中,抗体药物的品种数量位居...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
北京智道顾问有限责任公司 2013-2017 年中国抗体药物行业现状 与发展趋势及前景预测报告 智库在线(www.zikoo.com)秉承“智通库汇 ”的服务理 念,不断收集和更新...
很大一部分抗体药物都已迈入重磅炸弹行 列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2017年中国抗体药物市场专项调研与发展策略研究报告_经济/市场_经管营销_专业...年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2011-2012 ...
2013-2018 年中国抗体药物行业市场 运行态势及投资前景预测报告 2013-2018 年中国...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
(注:由于多用户报告的各类客户信息关 注点不同,上述所涉及的内容可根据具体需求进行调整) 2013-2018 年中国抗体药物行业市场前瞻及投资咨询报告 目录 第一章 抗体...
很大 一部分抗体药物都已迈入重磅炸弹行列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2018年中国单克隆抗体药物行业市场行情动态及未来发展趋势预测分析报告_经济/...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
2013-2018 年中国单克隆抗体药物行 业市场监测与投资前景分析报告 2013-2018 年...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
热门文档